Integra LifeSciences Holdings Corporation
IART
$13.57
$0.564.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.74% | 11.49% | -0.41% | 9.68% | -3.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.74% | 11.49% | -0.41% | 9.68% | -3.14% |
| Cost of Revenue | 12.41% | 12.04% | 6.50% | 18.64% | 5.01% |
| Gross Profit | -2.14% | 11.12% | -5.02% | 4.42% | -7.99% |
| SG&A Expenses | 2.81% | 22.48% | 11.33% | 11.87% | 1.81% |
| Depreciation & Amortization | 21.72% | 22.45% | 17.21% | 22.50% | -2.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.94% | 17.92% | 9.33% | 14.66% | 2.63% |
| Operating Income | -22.28% | -15.61% | -55.97% | -18.25% | -33.49% |
| Income Before Tax | -474.30% | -21.89% | -209.42% | -497.10% | -117.56% |
| Income Tax Expenses | -143.36% | -65.58% | -988.63% | -673.06% | -135.10% |
| Earnings from Continuing Operations | -670.89% | -2.01% | -154.85% | -396.41% | -113.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -670.89% | -2.01% | -154.85% | -396.41% | -113.54% |
| EBIT | -22.28% | -15.61% | -55.97% | -18.25% | -33.49% |
| EBITDA | -3.38% | 1.69% | -46.49% | 2.85% | -22.78% |
| EPS Basic | -683.89% | -0.04% | -157.17% | -409.86% | -114.26% |
| Normalized Basic EPS | -42.28% | -25.37% | -71.13% | -24.23% | -37.80% |
| EPS Diluted | -683.89% | 0.40% | -158.33% | -420.40% | -114.55% |
| Normalized Diluted EPS | -42.28% | -25.37% | -71.08% | -24.05% | -37.46% |
| Average Basic Shares Outstanding | -1.64% | -1.98% | -4.07% | -4.39% | -5.05% |
| Average Diluted Shares Outstanding | -1.64% | -1.98% | -4.21% | -4.61% | -5.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |